Logo_Biofrontera_AG.png
Biofrontera Reports Full Year 2017 Financial Results
April 30, 2018 08:00 ET | Biofrontera AG
Leverkusen, Germany, April 30, 2018 (GLOBE NEWSWIRE) -- Biofrontera AG (NASDAQ: BFRA; Frankfurt Stock Exchange: B8F) (“Biofrontera” or the “Company”), an international biopharmaceutical...
Biofrontera announces preliminary unaudited sales revenues for the 1st Quarter 2018
April 12, 2018 10:53 ET | Biofrontera AG
Leverkusen, Germany, April 12, 2018 (GLOBE NEWSWIRE) -- Biofrontera AG (NASDAQ:BFRA) (ISIN: DE0006046113), the specialist for the treatment of sun-induced skin cancer, today announced preliminary...
Biofrontera AG Announces Partial Waiver of Lock-Up Agreement
March 15, 2018 10:15 ET | Biofrontera AG
LEVERKUSEN, Germany, March 15, 2018 (GLOBE NEWSWIRE) -- Biofrontera AG (NASDAQ:BFRA) (Frankfurt Stock Exchange:B8F) (the “Company”) announced today that The Benchmark Company, LLC, the managing...
Biofrontera AG Announces Closing of $US12.9 Million Firm Commitment Initial Public Offering of American Depositary Shares
February 16, 2018 16:05 ET | Biofrontera AG
LEVERKUSEN, Germany, Feb. 16, 2018 (GLOBE NEWSWIRE) -- Biofrontera AG (NASDAQ:BFRA) (Frankfurt Stock Exchange:B8F) (“Biofrontera” or the “Company”), an international biopharmaceutical company, today...
Biofrontera AG Announces Pricing of US$12 Million Firm Commitment Public Offering of American Depositary Shares and NASDAQ Listing
February 13, 2018 19:00 ET | Biofrontera AG
LEVERKUSEN, Germany, Feb. 13, 2018 (GLOBE NEWSWIRE) -- Biofrontera AG (NASDAQ:BFRA) (Frankfurt Stock Exchange:B8F) (“Biofrontera” or the “Company”), an international biopharmaceutical company, today...
Biofrontera AG: Biofrontera Reports Full Year 2015 Financial Results
April 15, 2016 02:04 ET | Biofrontera AG
LEVERKUSEN, Germany, April 15, 2016 (GLOBE NEWSWIRE) -- Biofrontera AG (FSE: B8F), the specialist for sun-induced skin cancer, today reported its full year 2015 financial results for the year ended 31...
Biofrontera AG: Notice of Annual Results 2016
April 07, 2016 08:06 ET | Biofrontera AG
LEVERKUSEN, Germany, April 7, 2016 (GLOBE NEWSWIRE) -- Biofrontera AG (AIM:B8F), the specialist for sun-induced skin cancer, will be announcing its financial results for the twelve-month period ended...
Biofrontera Announces NDA Progress Update for BF-200 ALA
April 04, 2016 07:04 ET | Biofrontera AG
FDA issued suggested labeling for BF-200 ALA for treatment of actinic keratosis (AK) FDA has not requested any further data NDA on track LEVERKUSEN, Germany, April 4, 2016 (GLOBE...
Biofrontera AG: Biofrontera AG resolves on capital increase
February 16, 2016 11:57 ET | Biofrontera AG
Leverkusen, Germany, Feb. 16, 2016 (GLOBE NEWSWIRE) -- The Management Board of Biofrontera AG (FSE: B8F) has resolved on 12 February 2016, with the approval of the Supervisory Board, to increase the...
Biofrontera AG: Pivotal Phase III Data Demonstrate Significant Efficacy and Excellent Safety for BF-200 ALA Treatment of Superficial Skin Cancer
February 11, 2016 10:37 ET | Biofrontera AG
LEVERKUSEN, Germany, Feb. 11, 2016 (GLOBE NEWSWIRE) -- Biofrontera AG (FSE: B8F), the specialist for sun-induced skin cancer, presents data from three pivotal Phase III trials for its lead drug...